Jorn L. J. C. Assmann

Jorn L. J. C. Assmann

Auto-generated profile, based on publicly available information

Jorn L. J. C. Assmann

Laboratory of Medical Immunology, Department of Immunology, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in Blood
Verified
Journal Article
Closed access
PDF file
PHPaul J. Hengeveld
Paul J. Hengeveld
MKMichèle Y. van der Klift
Michèle Y. van der Klift
PKP. Martijn Kolijn
P. Martijn Kolijn
FDFrédéric Davi
Frédéric Davi
FKFrançois G. Kavelaars
François G. Kavelaars
ALAnton W. Langerak
Anton W. Langerak
The sensitivity of conventional techniques for reliable quantification of minimal/measurable residual disease (MRD) in chronic lymphocytic leukemia (CLL) is limited to MRD 10−4. Measuring MRD <10−4 could help to further distinguish between patients with CLL with durable remission and those at risk of early relapse. We herein present an academically developed immunoglobulin heavy-chain variable (IGHV) leader-based next-generation sequencing (NGS) assay for the quantification of MRD in CLL. We demonstrate, based on measurements in contrived MRD samples, that the linear range of detection and quantification of our assay reaches beyond MRD 10−5. If provided with sufficient DNA input, MRD can be detected down to MRD 10−6. There was high interassay concordance between measurements of the IGHV leader-based NGS assay and allele-specific oligonucleotide quantitative polymerase chain reaction (PCR) (r = 0.92 [95% confidence interval {CI}, 0.86-0.96]) and droplet digital PCR (r = 0.93 [95% CI, 0.88-0.96]) on contrived MRD samples. In a cohort of 67 patients from the CLL11 trial, using MRD 10−5 as a cutoff, undetectable MRD was associated with superior progression-free survival (PFS) and time to next treatment. More important, deeper MRD measurement allowed for additional stratification of patients with MRD <10−4 but ≥10−5. PFS of patients in this MRD range was significantly shorter, compared with patients with MRD <10−5 (hazard ratio [HR], 4.0 [95% CI, 1.6-10.3]; P = .004), but significantly longer, compared with patients with MRD ≥10−4 (HR, 0.44 [95% CI, 0.23-0.87]; P = .018). These results support the clinical utility of the IGHV leader-based NGS assay.

6 December 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
JAJorn L. J. C. Assmann
Jorn L. J. C. Assmann
LLLeticia G. Leon
Leticia G. Leon
CSChristiaan Stavast
Christiaan Stavast
SBSanne E. van Den Bogaerdt
Sanne E. van Den Bogaerdt
JSJoyce Schilperoord-Vermeulen
Joyce Schilperoord-Vermeulen
ALAnton W. Langerak
Anton W. Langerak
T-LGL cells arise as a consequence of chronic antigenic stimulation and inflammation and thrive because of constitutive activation of the STAT3 and ERK pathway. Notably, in 40% of patients, constitutive STAT3 activation is due to STAT3 activating mutations, whereas in 60% this is unknown. As miRNAs are amongst the most potent regulators in health and disease, we hypothesized that aberrant miRNA expression could contribute to dysregulation of these pathways. miRNA sequencing in T-LGL leukemia cases and aged-matched healthy control TEMRA cells revealed overexpression of miR-181a. Furthermore, geneset enrichment analysis (GSEA) of downregulated targets of miR-181a implicated involvement in regulating STAT3 and ERK1/2 pathways. Flow cytometric analyses showed increased SOCS3+ and DUSP6+ T-LGL cells upon miR-181a inhibition. In addition, miR-181a-transfected human CD8+ T cells showed increased basal STAT3 and ERK1/2 phosphorylation. By using TL1, a human T-LGL cell line, we could show that miR-181a is an actor in T-LGL leukemia, driving STAT3 activation by SOCS3 inhibition and ERK1/2 phosphorylation by DUSP6 inhibition and verified this mechanism in an independent cell line. In addition, miR-181a inhibition resulted in a higher sensitivity to FAS-mediated apoptosis. Collectively, our data show that miR-181a could be the missing link to explain why STAT3-unmutated patients show hyperactive STAT3.

7 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
PHPaul Hengeveld
Paul Hengeveld
PKPieter Martijn Kolijn
Pieter Martijn Kolijn
JDJeroen Demmers
Jeroen Demmers
WDWouter Doff
Wouter Doff
JDJulie Dubois
Julie Dubois
ALAnton W. Langerak
Anton W. Langerak
It remains challenging in chronic lymphocytic leukemia (CLL) to distinguish between patients with favorable and unfavorable time to first treatment (TTFT). Additionally, the downstream protein correlates of well-known molecular features of CLL are not always clear. To address this, we selected 40 CLL patients with TTFT ≤ 24 months and compared their B cell intracellular protein expression with 40 age- and sex-matched CLL patients with TTFT > 24 months using mass spectrometry. In total, 3268 proteins were quantified in the cohort. IGHV mutational status and trisomy 12 were most impactful on the CLL proteome. Comparing cases to controls, five proteins were significantly upregulated, whereas three proteins where significantly downregulated. Of these, only THEMIS2, a signaling protein acting downstream of the B cell receptor, was significantly associated with TTFT, independently of IGHV and TP53 mutational status (HR 2.49, [95%CI 1.62–3.84], P < 0.001). This association was validated on the mRNA and protein level by qPCR and ELISA, respectively. Analysis of two independently generated RNA sequencing and mass spectrometry datasets confirmed the association between THEMIS2 expression and clinical outcome. In conclusion, we present a comprehensive characterization of the proteome of untreated CLL and identify THEMIS2 expression as a putative biomarker of TTFT.